KR20210056325A - 지질단백질 형성 감소 및 대동맥판막 경화증 및 대동맥 협착증 치료용 조성물 및 방법 - Google Patents

지질단백질 형성 감소 및 대동맥판막 경화증 및 대동맥 협착증 치료용 조성물 및 방법 Download PDF

Info

Publication number
KR20210056325A
KR20210056325A KR1020217003215A KR20217003215A KR20210056325A KR 20210056325 A KR20210056325 A KR 20210056325A KR 1020217003215 A KR1020217003215 A KR 1020217003215A KR 20217003215 A KR20217003215 A KR 20217003215A KR 20210056325 A KR20210056325 A KR 20210056325A
Authority
KR
South Korea
Prior art keywords
antibody
seq
subject
orticumab
fragment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020217003215A
Other languages
English (en)
Korean (ko)
Inventor
버트런드 씨. 량
Original Assignee
앱센트라 엘엘시
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 앱센트라 엘엘시 filed Critical 앱센트라 엘엘시
Publication of KR20210056325A publication Critical patent/KR20210056325A/ko
Ceased legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/92—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving lipids, e.g. cholesterol, lipoproteins, or their receptors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/02—Screening involving studying the effect of compounds C on the interaction between interacting molecules A and B (e.g. A = enzyme and B = substrate for A, or A = receptor and B = ligand for the receptor)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Organic Chemistry (AREA)
  • Biophysics (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Endocrinology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
KR1020217003215A 2018-07-02 2019-07-01 지질단백질 형성 감소 및 대동맥판막 경화증 및 대동맥 협착증 치료용 조성물 및 방법 Ceased KR20210056325A (ko)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201862693218P 2018-07-02 2018-07-02
US62/693,218 2018-07-02
US201862697353P 2018-07-12 2018-07-12
US62/697,353 2018-07-12
PCT/US2019/040196 WO2020010024A1 (en) 2018-07-02 2019-07-01 Compositions and methods for reduction of lipoprotein a formation and treatment of aortic valve sclerosis and aortic stenosis

Publications (1)

Publication Number Publication Date
KR20210056325A true KR20210056325A (ko) 2021-05-18

Family

ID=69060543

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020217003215A Ceased KR20210056325A (ko) 2018-07-02 2019-07-01 지질단백질 형성 감소 및 대동맥판막 경화증 및 대동맥 협착증 치료용 조성물 및 방법

Country Status (7)

Country Link
US (1) US20210155682A1 (https=)
EP (1) EP3817768A4 (https=)
JP (1) JP7513533B2 (https=)
KR (1) KR20210056325A (https=)
CN (1) CN112839672A (https=)
CA (1) CA3105071A1 (https=)
WO (1) WO2020010024A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10858422B2 (en) 2016-05-31 2020-12-08 Abcentra, Llc Methods for treating systemic lupus erythematosus with an anti-apolipoprotein B antibody
CA3172880A1 (en) * 2020-04-27 2021-11-04 Sotirios Tsimikas Isoform-independent antibodies to lipoprotein(a)
WO2024194686A2 (en) 2023-03-17 2024-09-26 Oxitope Pharma B.V. Anti-phosphocholine antibodies and methods of use thereof

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6727102B1 (en) * 1997-06-20 2004-04-27 Leuven Research & Development Vzw Assays, antibodies, and standards for detection of oxidized and MDA-modified low density lipoproteins
GB0517878D0 (en) * 2005-09-02 2005-10-12 Bioinvent Int Ab Immunotherapeutic treatment
GB0624500D0 (en) * 2006-12-07 2007-01-17 Istituto Superiore Di Sanito A novel passive vaccine for candida infections
UA100255C2 (uk) * 2007-12-28 2012-12-10 Біоінвент Інтернешенл Аб Фармацевтична композиція
AR076640A1 (es) * 2009-03-06 2011-06-29 Genentech Inc Formulacion con anticuerpo. metodo para estabilizar anticuerpo. articulo de manufactura
ES2992345T3 (es) * 2011-09-16 2024-12-11 Regeneron Pharma Métodos para reducir los niveles de lipoproteína(a) mediante la administración de un inhibidor de la proproteína convertasa subtilisina kexina-9 (PCSK9)
AU2015231713B2 (en) * 2014-03-17 2020-11-19 Regeneron Pharmaceuticals, Inc. Methods for reducing cardiovascular risk
CA2874083C (en) * 2014-12-05 2024-01-02 Universite Laval Tdp-43-binding polypeptides useful for the treatment of neurodegenerative diseases

Also Published As

Publication number Publication date
JP7513533B2 (ja) 2024-07-09
JP2021529766A (ja) 2021-11-04
EP3817768A1 (en) 2021-05-12
US20210155682A1 (en) 2021-05-27
EP3817768A4 (en) 2022-07-06
CN112839672A (zh) 2021-05-25
CA3105071A1 (en) 2020-01-09
WO2020010024A1 (en) 2020-01-09

Similar Documents

Publication Publication Date Title
JP5795833B2 (ja) スフィンゴシン−１−リン酸と結合させるための組成物および方法
JP7173618B2 (ja) アルファ－シヌクレインに対する抗体およびその用途
JP7629651B2 (ja) Ｍ（ｈ）ｄｍ２／４に対する抗体、ならびにがんの診断および処置におけるそれらの使用
US12458694B2 (en) Methods for treatment of accelerated atherosclerosis and rheumatoid arthritis with an anti-Apo B100 antibody
WO2018067819A1 (en) Compositions and methods for treatment of cancers
TW202128764A (zh) 用於活化整合素之組合物及方法
US9738717B2 (en) Hybridoma clones, monoclonal antibodies, and methods of use
KR20210056325A (ko) 지질단백질 형성 감소 및 대동맥판막 경화증 및 대동맥 협착증 치료용 조성물 및 방법
CA3227057A1 (en) Use of alpha-enolase antagonist in treating fibrotic diseases
JP2020518668A (ja) ｘＣＴ抗体に関連する組成物および方法
JP2024534083A (ja) 補体代替経路阻害剤を用いて鎌状赤血球症又はベータサラセミアを治療する方法
WO2022130318A2 (en) Antibodies against integrin alpha 11 beta 1
JP7756452B2 (ja) 肺、腎臓、または肝臓の線維症疾患の処置に使用するためのｐｓｍｐアンタゴニスト
WO2025006989A2 (en) Methods for detection and treatment of cancer
WO2017174017A1 (zh) 前蛋白转化酶枯草溶菌素kexin 9型的结合蛋白及其应用
HK40112898A (zh) 抗alk1抗体及其使用方法
WO2025195402A1 (zh) 靶向trop2的抗体-药物偶联物治疗癌症的方法

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

E13 Pre-grant limitation requested

Free format text: ST27 STATUS EVENT CODE: A-2-3-E10-E13-LIM-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-NAP-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13 Application amended

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-NAP-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

B15 Application refused following examination

Free format text: ST27 STATUS EVENT CODE: N-2-6-B10-B15-EXM-PE0601 (AS PROVIDED BY THE NATIONAL OFFICE)

PE0601 Decision on rejection of patent

St.27 status event code: N-2-6-B10-B15-exm-PE0601

T11 Administrative time limit extension requested

Free format text: ST27 STATUS EVENT CODE: U-3-3-T10-T11-OTH-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T13-X000 Administrative time limit extension granted

St.27 status event code: U-3-3-T10-T13-oth-X000